Literature DB >> 23159991

Correlation between benign prostatic hyperplasia and inflammation.

Yakup Bostanci1, Amir Kazzazi, Shabnam Momtahen, Juliana Laze, Bob Djavan.   

Abstract

PURPOSE OF REVIEW: This review aims to evaluate the available evidence on the role of prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). RECENT
FINDINGS: Although there is still no evidence of a causal relation, accumulating evidence suggests that inflammation may contribute to the development of BPH and lower urinary tract symptoms (LUTS). Inflammatory infiltrates are frequently observed in prostate tissue specimens from men with BPH and the presence or degree of inflammation has been found to be correlated with prostate volume and weight. The inflammatory injury may contribute to cytokine production by inflammatory cells driving local growth factor production and angiogenesis in the prostatic tissue. This proinflammatory microenvironment is closely related to BPH stromal hyperproliferation and tissue remodeling with a local hypoxia induced by increased oxygen demands by proliferating cells which supports chronic inflammation as a source of oxidative stress leading to tissue injury in infiltrating area.
SUMMARY: Although the pathogenesis of BPH is not yet fully understood and several mechanisms seem to be involved in the development and progression, recent studies strongly suggest that BPH is an immune inflammatory disease. The T-cell activity and associated autoimmune reaction seem to induce epithelial and stromal cell proliferation. Further understanding of the role of inflammation in BPH and clinical detection of this inflammation will expand the understanding of BPH pathogenesis and its histologic and clinical progression, allow risk stratification for patients presenting with BPH-related LUTS, and suggest novel treatment strategies.

Entities:  

Mesh:

Year:  2013        PMID: 23159991     DOI: 10.1097/MOU.0b013e32835abd4a

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  53 in total

1.  Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth.

Authors:  Fernanda Chagas-Silva; Jéssica Barbosa Nascimento-Viana; Luiz Antonio S Romeiro; Luana C Barberato; François Noël; Claudia Lucia Martins Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

2.  Expansion of prostate epithelial progenitor cells after inflammation of the mouse prostate.

Authors:  Liang Wang; Marloes Zoetemelk; Brahmananda R Chitteti; Timothy L Ratliff; Jason D Myers; Edward F Srour; Hal Broxmeyer; Travis J Jerde
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-29

3.  Elevated red blood cell distribution width in benign prostatic hyperplasia patients with metabolic syndrome.

Authors:  Xingmo Dong; Ying Liao; Kaihong Chen; Yong Fang; Weiguo Li; Jiande Chen; Lixia You; Shuiping Li
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial .

Authors:  Ibrahim Kulac; Berrak Gumuskaya; Charles G Drake; Beverly Gonzalez; Kathryn B Arnold; Phyllis J Goodman; Alan R Kristal; M Scott Lucia; Ian M Thompson; William B Isaacs; Angelo M De Marzo; Elizabeth A Platz
Journal:  Prostate       Date:  2016-06-21       Impact factor: 4.104

Review 5.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

6.  Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes.

Authors:  Zhe Chen; Li Miao; Xia Gao; Guang Wang; Yuan Xu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

7.  Interleukin-driven insulin-like growth factor promotes prostatic inflammatory hyperplasia.

Authors:  Alana M Hahn; Jason D Myers; Eliza K McFarland; Sanghee Lee; Travis J Jerde
Journal:  J Pharmacol Exp Ther       Date:  2014-10-07       Impact factor: 4.030

8.  DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate.

Authors:  Rongbin Ge; Zongwei Wang; Seth K Bechis; Alexander G Otsetov; Shengyu Hua; Shulin Wu; Chin-Lee Wu; Shahin Tabatabaei; Aria F Olumi
Journal:  Am J Pathol       Date:  2015-02-17       Impact factor: 4.307

9.  Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.

Authors:  Petra Popovics; Andrew V Schally; Luis Salgueiro; Krisztina Kovacs; Ferenc G Rick
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-25       Impact factor: 11.205

10.  Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Authors:  Ferenc G Rick; Andrew Abi-Chaker; Luca Szalontay; Roberto Perez; Miklos Jaszberenyi; Arumugam R Jayakumar; Nagarajarao Shamaladevi; Karoly Szepeshazi; Irving Vidaurre; Gabor Halmos; Awtar Krishan; Norman L Block; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.